Regeneron Pharmaceuticals, Inc.(REGN)Earnings, Financials & Key RatiosRegeneron Pharmaceuticals, Inc. (REGN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a strong liquidity position with a 3.57 current ratio, the volatility in cash conversion and potential margin compression from biosimilars warrant a cautious approach at the current 15.26 P/E multiple.
Regeneron Pharmaceuticals, Inc. (REGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Regeneron Pharmaceuticals, Inc. (REGN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $9.47vs $8.91+6.3% | $3.6Bvs $3.5B+3.6% |
| Q1 2026 | Jan 30, 2026 | $11.44vs $10.74+6.5% | $3.9Bvs $3.8B+1.9% |
| Q4 2025 | Oct 28, 2025 | $11.83vs $9.65+22.6% | $3.8Bvs $3.6B+4.5% |
| Q3 2025 | Aug 1, 2025 | $12.89vs $8.43+52.9% | $3.7Bvs $3.3B+11.8% |
Recent stock market news and headlines for Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Key metrics vs top competitors for Regeneron Pharmaceuticals, Inc. (REGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $676.23 | $70.26B | 16.30 | 0.99% | 31.41% | 14.87% | 0.5% | |
| $205.70 | $30.37B | 23.30 | 1.39% | 13.92% | 7.55% | — | |
| $522.25 | $132.84B | 34.09 | 9.57% | 35.4% | 23.93% | — | |
| $118.05 | $23.58B | 18.42 | 21.22% | 26.71% | 29.31% | — | |
| $60.35 | $11.61B | 33.53 | 12.87% | 8.29% | 4.41% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — |
Regeneron Pharmaceuticals, Inc. (REGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Regeneron Pharmaceuticals, Inc. (REGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 29, 2026·SEC
Apr 8, 2026·SEC
Jan 30, 2026·SEC
Get notified when REGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Regeneron Pharmaceuticals, Inc. (REGN) stock FAQ — growth, dividends, profitability & financials explained
Regeneron Pharmaceuticals, Inc. (REGN) reported $14.92B in revenue for fiscal year 2025. This represents a 61807% increase from $24.1M in 1996.
Regeneron Pharmaceuticals, Inc. (REGN) grew revenue by 1.0% over the past year. Growth has been modest.
Yes, Regeneron Pharmaceuticals, Inc. (REGN) is profitable, generating $4.42B in net income for fiscal year 2025 (31.4% net margin).
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend with a yield of 0.50%. This makes it attractive for income-focused investors.
Regeneron Pharmaceuticals, Inc. (REGN) has a return on equity (ROE) of 14.9%. This is reasonable for most industries.
Regeneron Pharmaceuticals, Inc. (REGN) generated $4.16B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
